How are WAT strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the WAT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 35.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,032.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a WAT strangle?

The breakeven for the WAT strangle priced on this page is roughly $339.68 and $400.33 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current WAT market-implied 1-standard-deviation expected move is approximately 10.18%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current WAT implied volatility affect this strangle?

WAT ATM IV is at 35.50% with IV rank near 30.20%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

WAT Strangle Strategy

WAT (Waters Corporation), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers.

WAT (Waters Corporation) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $24.41B, a trailing P/E of 68.46, a beta of 1.20 versus the broader market, a 52-week range of 275.05-414.15, average daily share volume of 1.0M, a public-listing history dating back to 1995, approximately 8K full-time employees. These structural characteristics shape how WAT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.20 places WAT roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 68.46 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a strangle on WAT?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current WAT snapshot

As of June 29, 2026, spot at $369.56, ATM IV 35.50%, IV rank 30.20%, expected move 10.18%. The strangle on WAT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on WAT specifically: WAT IV at 35.50% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 10.18% (roughly $37.61 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated WAT expiries trade a higher absolute premium for lower per-day decay. Position sizing on WAT should anchor to the underlying notional of $369.56 per share and to the trader's directional view on WAT stock.

WAT strangle setup

The WAT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With WAT near $369.56, the first option leg uses a $390.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed WAT chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 WAT shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$390.00	$4.48
Buy 1	Put	$350.00	$5.85

WAT strangle risk and reward

Net Premium / Debit: -$1,032.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$1,032.50
Breakeven(s): $339.68, $400.33
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

WAT strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on WAT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$33,966.50
$81.72	-77.9%	+$25,795.43
$163.43	-55.8%	+$17,624.37
$245.14	-33.7%	+$9,453.30
$326.85	-11.6%	+$1,282.24
$408.56	+10.6%	+$823.83
$490.27	+32.7%	+$8,994.89
$571.98	+54.8%	+$17,165.96
$653.70	+76.9%	+$25,337.02
$735.41	+99.0%	+$33,508.09

When traders use strangle on WAT

Strangles on WAT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the WAT chain.

WAT thesis for this strangle

The market-implied 1-standard-deviation range for WAT extends from approximately $331.95 on the downside to $407.17 on the upside. A WAT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current WAT IV rank near 30.20% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on WAT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, WAT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to WAT-specific events.

WAT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. WAT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move WAT alongside the broader basket even when WAT-specific fundamentals are unchanged. Always rebuild the position from current WAT chain quotes before placing a trade.

Frequently asked questions

What is a strangle on WAT?: A strangle on WAT is the strangle strategy applied to WAT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With WAT stock trading near $369.56, the strikes shown on this page are snapped to the nearest listed WAT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are WAT strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the WAT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 35.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,032.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a WAT strangle?: The breakeven for the WAT strangle priced on this page is roughly $339.68 and $400.33 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current WAT market-implied 1-standard-deviation expected move is approximately 10.18%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on WAT?: Strangles on WAT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the WAT chain.
How does current WAT implied volatility affect this strangle?: WAT ATM IV is at 35.50% with IV rank near 30.20%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.